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Behçet’s Disease: An Enigmatic 
Malady with Plethoric Expressions
Shamaz Mohamed and Abhilash R. Krishnan
Abstract
Behçet’s disease (BD) is a chronic, inflammatory, repetitive, debilitating 
systemic vasculitis with conglomerate system involvement of uncharted aetiology 
portrayed by the triad of oral ulcers, genital ulcers and cutaneous lesions. Behçet’s 
disease has a universal distribution with a predominance among populace with 
higher prevalence of human leukocyte antigen (HLA) B5 and its split, HLA-B51, 
in the Mediterranean basin, the Middle East and Far East. This ailment is presently 
acknowledged to be a multisystem disorder with mucocutaneous, ocular, intestinal, 
articular, vascular, urogenital, musculoskeletal, cardiopulmonary and neurologic 
systems and hence bears significant organ sinistering morbidity and mortality. 
The diagnosis of Behçet’s disease relies on scrupulous history, identification of its 
emblematic clinical countenance as per the diagnostic criteria construed by the 
International Study Group (ISG) and examination of all pertinent systems and 
excluding other systemic rheumatic diseases. However, there is a lag in diagnosis 
because of its plethoric presentations and a dearth of specific biomarkers. The 
multiple organ and tissue involvement of Behçet’s disease necessitates an interdis-
ciplinary approach from various health specialities since a general and an organ-
specific approach is mandatory. Prime concern is to control the active periods of 
the disease which is achieved by different anti-inflammatory drugs, steroids or 
immunomodulators.
Keywords: Behçet’s disease, triple symptom complex, Adamantiades-Behçet’s disease, 
oral ulcers, aphthous stomatitis, vasculitis, silk road disease
1. Introduction
Behçet’s disease (BD) is described as a severely debilitating chronic, recurrent, 
multisystem vascular inflammatory disorder characterised by the triad of oral 
and genital ulceration and ocular lesions. This exemplary presentation would have 
been probably first identified by Hippocrates [1, 2]. Even though Behçet’s disease 
was first identified by the father of medicine in the fifth century BC, there were no 
literature representations for this entity till 1930, and then a Greek ophthalmologist 
Benediktos Adamantiades presented one of his case of relapsing eye lesions associ-
ated with genital ulceration and arthritis in a 20-year-old male; since then entity has 
been added with a synonym “Adamantiades-Behçet’s disease” [3–6]. Further to its 
classic expression of orogenital ulceration and ocular lesions, the conditions seem to 
involve the musculoskeletal system, nervous system, gastrointestinal tract, vascular 
beds, urogenital tract and cardiopulmonary system, so Behçet’s disease have a high 
morbidity and mortality particularly in males with early age onset [7, 8].  
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The self-limiting inflammation and the relapsing episodes of clinical manifesta-
tions are the hallmark of Behçet’s disease [9]. Frequency and span of regression are 
uncertain and show no distinguishable pattern of onset.
Although Behçet’s disease has a worldwide distribution, it is more rampant in 
Turkish population, where the prevalence is about 421 cases per 100,000 and 13 to 
20 cases per 100,000 population in China, Korea, Japan and the Middle East  
[10, 11]. Behçet’s disease is most commonly diagnosed in the second and third 
decades of life especially during the reproductive years and shows a female predilec-
tion among Europeans. Behçet’s disease rarely occurs prior to puberty and after the 
fifth decade of life. Behçet’s disease developing in early age has shown to have severe 
clinical manifestations and mortality. Familial occurrences have been reported in 
various literatures but are unusual, and the aetiology of Behçet’s disease remains 
cryptic [12–18]. The widely accepted hypothesis is that of an inappropriate inflam-
matory response provoked by an infectious agent in a genetically liable host [19].
Diagnosis of Behçet’s disease is based on the criteria developed by the 
International study group (ISG) in 1990 and International Criteria for Behçet’s 
Disease (ICBD) [20]. The ICBD was developed with the intention of bettering the 
ISG criteria that did not consist of nervous system, vascular and gastrointestinal 
involvement that are severe but rather infrequent complications of Behçet’s disease. 
A recent study conducted in the United Kingdom has compared the efficacy of ISG 
and ICBD diagnostic criteria among their patients with Behçet’s disease and con-
cluded that the sensitivity was higher for ICBD than ISG criteria, but the specificity 
of ICBD was much lower than the ISG criteria [20–22].
Management is aimed to alleviate symptoms, resolve inflammation, restrain tis-
sue damage, dwindle frequency and severity and avoid lethal complications. A mul-
titude of treatment modalities have been proposed for managing Behçet’s disease 
ranging from anti-inflammatory to immunomodulators and biologic monoclonal 
antibodies. Detrimental ramifications are a main concern since it requires long-term 
medication [8].
2. Epidemiology
Behçet’s disease is observed to have a worldwide distribution. However, it is 
seen commonly among the inhabitants of the historic Silk Road, which was sup-
posed to be an old trading route that linked Japan and China in the Far East to the 
Mediterranean Sea, including countries such as Turkey and Iran. Therefore, Behçet’s 
disease is also known by the synonym “Silk Road disease” [23]. Behçet’s disease has 
a highest prevalence rate in Turkey, where the estimated prevalence is about 421 
per 100,000 population followed by Iran, Israel and Japan [24]. It is rarely reported 
in African countries and the USA [23] as well as Australia, where the prevalence 
remains unknown but with an annual incidence of 0.6% (Table 1) [25].
Two studies conducted in Korea and Turkey in 2016 and 2017 reported the 
prevalence of Behçet’s disease. A study conducted in Korea estimated the prevalence 
of Behçet’s disease, and change in prevalence rate over time from the Korean health-
care big data that consists of medical institution claims data concerning diagnosis, 
prescription medicines and surgical treatment and represents the total popula-
tion. The database was reviewed for patients diagnosed to have Behçet’s disease 
during the year 2011 and 2015. The diagnosis was based on the Korean Standard 
Classification of Diseases (KCD). The estimated prevalence was about 35.0 per 
100,000 population which was a little more than the previously reported prevalence 
of 30.2 per 100,000 in Korea. The change in prevalence rate was also estimated 
during the time period of 2011 and 2015 and concluded that there is a creeping 
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escalation in the annual prevalence rate between 2011 and 2015. The prevalence 
rate was 32.8 per 100,000 in 2011, 34.0 per 100,000 in 2012, 34.6 per 100,000 in 
2013, 35.5 per 100,000 in 2014 and 35.7 per 100,000 in 2015. The prevalence would 
have been more since patients with milder form of the disease have not come for 
treatment. Females had a higher prevalence, with a female-to-male ratio of 1:0.54 in 
2011 and 1:0.56 in 2015 [26].
Another study conducted in Northern Turkey showed a prevalence of Behçet’s 
disease in 600/100,000 population who have crossed their second decade of life 
and is considered as the highest prevalence reported in the literature so far [27]. 
Nonetheless this conclusion seems to be biased since there are methodological errors. 
Patients were randomly selected from the 52 urban and 33 rural general practices 
of a city and are invited for an examination and interview by three dermatologists. 
As per the authors, the invited sample would well represent the whole population 
since all individuals are recorded in general practices. Eye examination and pathergy 
test were performed in suspected individuals. Individuals compatible to ISG criteria 
were diagnosed as Behçet’s disease. However, the total number of individuals who 
were invited for interview was not mentioned. Authors reported that 2325 of 2428 
individuals interviewed were included in the study, of which 1290 were females and 
1035 were males. Symptomatic individuals may have responded to the invitation, 
which might have led to a higher prevalence estimate. Authors have also reported 
increased prevalence of Behçet’s disease in females (860/100,000) compared to 
males (140/100,000) (p = 0.022) which does not correlate with the previous studies 
conducted in Turkey, since they concluded no significant gender predilections [27].
A recent meta-analysis that included 45 prevalence studies suggested that even 
though there was clearly a wide variation across countries, the overall prevalence of 
Behçet’s disease were 10.3/100,000. The estimated prevalence was 119.8/100,000 
for Turkey, 31.8/100,000 for the Middle East, 4.5/100,000 for Asia and 3.3/100,000 
for Europe [28]. A meta-regression analysis showed that classification criteria, study 
period or reference type had hardly any effect and study design was the deciding fac-
tor for Behçet’s disease prevalence in these studies. The authors have also suggested 
that true geographic variations and different study methods are the possible factors 
responsible for the large variation in Behçet’s disease prevalence across countries.
Prevalence per one lakh population Country
Turkey 421
Iran 80
Saudi Arabia 20
Iraq 17
Israel 15.2
Japan 13.5
France 7.1
USA 5.2
Sweden 4.9
Germany 2.26
Portugal 1.53
UK 0.64
Table 1. 
Worldwide prevalence of Behçet’s disease [24].
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Two studies conducted in Korea reported on the clinical manifestations of 
Behçet’s disease patients according to gender [29, 30]. The first study was carried out 
by a rheumatology department of a university hospital in Turkey, which assessed 
the prevalence between male and female with Behçet’s disease in a retrospective 
chart review of 329 patients [29]. The study included patients who fulfilled the ISG 
criteria. Data on demographic features of the patients, family history, age of onset, 
manifestations of Behçet’s, positive pathergy test and HLA-B51 were retrieved from 
patient charts. Among the 329 patients, 199 (60.4%) were males. A family history 
of Behçet’s disease was reported by 9.7% of the patients and a family history of oral 
ulcers by 22.5%. Early onset was observed in patients with a positive family history; 
this phenomenon is termed as genetic anticipation which had already been seen in 
previous studies [31]. Female patients had an early onset compared to males (23.0 
vs. 25.2 years, p < 0.05). Eye lesions were more common among males (42.2 vs. 
29.2%, p = 0.014). Vascular involvement was also more common among in males 
(44.7 vs. 15.3%, p < 0.001), whereas joint involvement and headache were common 
among women (70.0 vs. 49.2%, p < 0.001 for joint involvement and 60.0 vs. 36.2%, 
p < 0.001 for headache). Frequency of genital ulcers, nodular lesions, papulo-
pustular lesions and nervous system involvement was similar among males and 
females. Pathergy test was positive in 48.7% of the patients (52.4% among male and 
43.4% among female, p = 0.316). HLA-B51 was positive in 44.1% of Behçet’s disease 
patients, and the frequency was lower among men, but the difference was not that 
significant (38.8 vs. 50.6%, p = 0.106). The second study was conducted in Korea, 
which was a retrospective chart review of 193 patients, which analysed gender, age 
of onset of Behçet’s disease and HLA-B51 [30]. The study showed that there is an 
increased prevalence in females (67%), whereas other parameters like the mean age 
at onset, the mean disease duration, positive pathergy test and positive HLA-B51 
were similar in both males and females. Genital ulcers, peripheral joint involvement 
and inflammatory back pain were more common in females, while skin lesions were 
more frequent in males. In total, major organ involvement was present in 39% of the 
patients (uveitis, 27%; nervous system involvement, 7%; vascular involvement, 4% 
and gastrointestinal involvement, 11%), with similar frequency in both the genders. 
When clinical findings were compared based on onset of disease, patients with late 
onset (>40 years) had more nervous system involvement than those with an early 
onset (15.9 vs. 4.2%, p = 0.007).
Like the previous study, HLA-B51 positive patients had a history of early disease 
onset, but less nervous system (17.2 vs. 2.5%, p = 0.02) and gastrointestinal system 
(20.7 vs. 2.5%, p = 0.01) involvement than patients with negative HLA-B51 [32, 33].
A Japanese study conducted in 2015 analysed the change in disease phenotype 
over time among Behçet’s disease patients treated in seven hospitals in a district in 
mid-Japan between 1991 and 2015. Patients fulfilled the 1987 revised diagnostic 
criteria of the Behçet’s disease research committee; the Ministry of Health, Labour 
and Welfare of Japan was included in the study [34, 35]. This criterion classified the 
manifestations of Behçet’s disease into major and minor symptoms. Major symp-
toms include recurrent aphthous oral ulcers, skin lesions, ocular inflammation and 
genital ulcers, and minor symptoms include arthritis, intestinal ulcers, epididymi-
tis, vascular lesions and neuropsychiatric disease.
Those who have all four major symptoms during the clinical course are classified 
as complete, whereas those who have three major symptoms, two major and two 
minor symptoms, typical recurrent ocular inflammation and one or more major 
symptoms or typical recurrent ocular inflammation and two minor symptoms are 
classified as incomplete Behçet’s disease. Patients were divided into three groups 
as group A, diagnosed before 2000; group B, diagnosed between 2000 and 2007; 
and group C, diagnosed after 2008. Authors observed a decrease in the number of 
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patients with complete disease over time, suggesting a trend for milder disease in 
more recent years which could be due to usage of newer medicaments and aware-
ness about the disease. The male-to-female ratio and the age of onset of disease 
were not changed over time, whereas the frequency of genital ulcers and HLA-B51 
positivity decreased and gastrointestinal involvement frequency increased [34, 35].
Additionally, individuals migrated from countries with high prevalence of 
Behçet’s disease to countries with less prevalence rate were shown to have less risk of 
developing disease [36, 37]. Prevalence of Behçet’s disease among Turkish indi-
viduals in Germany is about 21/100,000, which, although higher than that of the 
German population, remains inferior to prevalence in Turkey [38].
Although Behçet’s disease is rare in Africans, two series have been published 
recently based on studies conducted in Nigeria and Dakar from the year 2007 to 
2011. Based on the observation by Italian authors, the prevalence of Behçet’s disease 
was found to be higher among immigrants when they analysed its prevalence 
among patients of Italian and non-Italian origin living in these areas.
A study conducted in the Netherlands estimated the prevalence of Behçet’s dis-
ease in patients with diverse ethnic origins residing in the Rotterdam area showed a 
prevalence of 1/100,000 population among Dutch Caucasians, 39/100,000 among 
Moroccans and 71/100,000 among Turks, suggesting that the prevalence among 
Moroccans is the same as in their countries of origin [39, 40].
3. Genetics
Peculiar geographical distribution, familial aggregation, polymorphisms in genes 
that control immune responses and correlation with HLA-B51 class I antigen are the 
four factors that are considered to contribute to Behçet’s disease susceptibility. Ohno 
in 1973 described the association of BD with HLA-B5 [39]. They demonstrated that 
HLA-B5 includes HLA-B51 and HLA-B52 as it has a heterogeneous composition. In 
major histocompatibility locus, HLA-B51 and HLA-B5701 were associated with the 
pathogenesis of the disease, mainly among populace alongside of ancient Silk Road. 
Although associations with HLA-A and HLA-C have been described, they are non-
specific and require confirmation. Other MHC genes such as TNF and MHC class I 
genes (MICA) are under study; the exact mechanism has not been fully understood. 
The association with HLA-B51 appears to be important in neutrophil activation. 
However, the presence of HLA-B51 alone is not ample to explain the manifestations 
of Behçet’s disease. A case series of Iranian patients showed association with HLA-
B35, HLA-B51, HLA-B52 and HLA-Bw4. Supplementary studies suggest associations 
with HLA-B15, HLA-B27, HLA-B57 and HLA-A26 [40].
Researches focused on single-nucleotide polymorphisms (SNPs) revealed that 
SNP which is in the HLA-B region between HLA-B and MICA genes is responsible 
for the relationship between HLA-B51 and Behçet’s disease. The epistatic interac-
tions with endoplasmic reticulum-associated aminopeptidase 1 (ERAP-1) has also 
been studied, and the authors suggested that the interaction of ERAP-1 and HLA-B 
has also been consistent, and these cytokines were apparently high in the peripheral 
blood mononuclear cells of patients with Behçet’s disease compared to the control 
group. Another conclusion was the unbalanced suppressor of cytokine signalling 
expression in patients with Behçet’s disease compared to controls [41].
A Chinese study stated that the polymorphisms of NOS3/rs1799983, a nitric 
oxide synthase gene, were found to be associated with the disease and the involve-
ment of CD16 and CD11c in Behçet’s disease susceptibility. Mutations in the familial 
Mediterranean fever (MEFV) gene were suggested by a meta-analysis of 8 studies 
which analysed 2538 patients and 2792 healthy controls. Researches also suggested 
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the associations of Toll-like receptors 7 (TLR7) and other nucleic acid-sensing genes 
of innate immunity-like inflammatory pathways such as IFI16 (a dsDNA cytosolic 
sensor and mediator of the AIM2-dependent inflammatory pathway) found to 
influence Behçet’s disease susceptibility [39]. Epigenetic studies with inverted 
repeat sequences (IRS) demonstrated that methylation level of IRS elements may 
influence the pathogenesis of the Behçet’s disease. Researches were done on genes 
related to apoptosis, but the results were not conclusive [41].
4. Pathogenesis
A multitude of factors that indicate the interaction between environmental, 
innate and adaptive immunity in the development of the disease has been already 
discussed in the Genetics section. Various researches have studied about the role 
of bacterial and viral agents in the development of Behçet’s disease, but the results 
were inconclusive. Streptococcus sanguinis and Herpesviridae were suspected as 
contributing extrinsic factors for the oral presentations in Behçet’s disease; the 
immune response to these microorganisms and bacterial plaque ecology may be 
affected in Behçet’s disease, leading to changes seen in the oral mucosa. However 
good prognosis was noticed in patients with good oral health status [41]. Recent 
studies in Behçet’s disease patients have demonstrated peculiar dysbiosis of the 
gut microbial flora with a notable drop in the production of butyrate. Butyrate can 
initiate the differentiation of regulatory T cells (T-reg), and thus, its decrease would 
lead to the reduction of regulatory T-cell response and activation of immunopatho-
logical T-cell effector responses. Predisposition to insulin resistance and metabolic 
syndrome in patients and reduction of angiopoietin 1 especially in patients with 
vascular involvement has been observed in other studies [42]. In an attempt to find 
out specific Behçet’s disease antigen, a Chinese research group demonstrated high 
IgG reactivity to an endothelial cell autoantigen [41].
Matzinger suggested the danger model, which occurs due to a continuous 
autoimmune cascade resulting from signals emitted by the affected cells of the host 
which will override the external stimulus. T cells and other antigen-presenting cells 
(APC) would command the process, which would be perpetuated on a favourable 
genetic terrain. Damage by a non-self-entity would trigger permanent aggression 
by activating an uncontrolled adaptive response. Because of their similarity to other 
pathogenic proteins, heat shock proteins (HSP60) could be involved. This adaptive 
reaction to external stimuli would persist in the permanent pathogenic presence via 
autoantigens that would activate dendritic T cells and B cells [40]. Thus, overex-
pression of proinflammatory cytokines especially Th1 and Th17 and probably asso-
ciation with genetic susceptibility may be the contributing factor for the increased 
inflammatory reaction in Behçet’s disease. Stimulated lymphocytes would activate 
neutrophils and endothelial cells, and HSPs would probably trigger innate and 
adaptive immune responses. Hypersensitivity to Streptococcus sanguinis is observed 
through the innate immune system. Microbial flora along with stress proteins in 
oral and periodontal tissues could cross-react with host tissues and stimulate the 
proliferation of autoreactive T-cell clones. HSPs would transfer antigenic peptides to 
APCs that could be identified by TLRs, triggering an endogenous signal of danger 
that would lead to the activation of innate and adaptive immune systems. They 
could also, directly or indirectly, cause increased expression of vascular endothelial 
growth factor by T cells, causing both endothelial cell damage and vasculitis.
Many studies have demonstrated the presence of IFN-gamma and IL-12 in periph-
eral blood of Behçet’s disease patients suggesting involvement of TH1 cells. Elevated 
IL-1, IL-6, IL-18, TNF-alpha and chemokines would reflect the activation of innate 
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and adaptive immune systems. Neutrophils are hyperactivated with increased phago-
cytosis, chemotaxis, superoxide and lysosomal enzyme production. Lymphocytes 
have also shown abnormal functions such as clonal expansion of autoreactive T cells 
specific for heat shock protein 60 peptides. In addition, gamma-delta T cells are abun-
dant in the blood and mucosal lesions of the affected individuals. Researchers have 
concluded that the interaction between T cells, neutrophils and antigen-presenting 
cells probably contributes to the pathogenesis of Behçet’s disease [40].
5. Clinical presentations
Behçet’s disease is a form of systemic vasculitis which affect almost all vascular-
ized systems (Table 2) and is characterised by episodes of relapses and remissions 
[9, 43, 44].
The triad of oral aphthae, genital ulcers and ocular lesions specifies the disease 
pattern even though Behçet’s disease has other multisystem involvement and several 
clinical manifestations.
Children exhibit more frequent perianal ulceration and more severe course of 
chorioretinitis and less frequent genital ulcers and vascular involvement [44, 45].
5.1 Eye manifestations
A meta-analysis of 18 articles which was performed by Horie et al. to assess the 
association between HLA-B51 and the ocular manifestations of Behçet’s disease 
among various ethnic group studies from Middle and Far East suggested that there 
was a strong association between HLA-B51 expression and ocular involvement, 
whereas studies from North Africa and Europe showed no association [46].
Accorinti et al. investigated demographic and clinical trends of 385 Behçet’s 
disease patients with uveitis seen over 44 years in a referral unit at Sapienza 
University in Rome, Italy. The cohort was divided into cohort 1, which included 
the patients seen from 1968 to 1992, and cohort 2 included the patients seen during 
1993 and 2011. Compared to the cohort 1, the cohort 2 has more female patients, 
more patients with milder disease (more frequent isolated anterior uveitis, less fre-
quent hypopyon) and more immunosuppressive use. Ocular complications such as 
optic atrophy, maculopathy and retinal neovascularisation and retinal detachment 
Manifestation Prevalence Prognosis Comments
Oral ulcers 47–83% Favourable Appear in all patients during the disease 
course
Genital ulcers 57–93% Favourable Lesion will leave a scar
Ocular lesions 30–70% Poor More frequent in males. Has high morbidity
Cutaneous lesions 38–99% Favourable Erythema nodosum more frequent in females
Joint involvement 45–60% Favourable Nondeforming and nonerosive
Cardiovascular involvement 7–49% Poor More frequent in males, high morbidity and 
mortality
Neurological involvement 5–10% Poor More frequent in males, high morbidity and 
mortality
Gastrointestinal involvement 3–26% Poor More frequent among Japanese
Table 2. 
Manifestations of Behçet’s disease.
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were significantly more common in cohort 1. The visual acuity at final evaluation 
was better in the second cohort. When considered both the cohorts, more severe 
findings were observed in males. From the above findings, the authors concluded 
that timely and aggressive management reduces ocular complications and facilitates 
better prognosis [47].
Even though uveitis is the common ocular pathology in Behçet’s disease, it is 
not a common cause of uveitis. The highest incidence of uveitis is reported by 
Mishima S from Japan [48], where it constitutes about 25%, but it is much rarer in 
other countries such as Brazil, where the incidence is 2% [49], and India, where the 
incidence is 1% reported by Sen DK from a study conducted in 94 Indian children 
[50]. The classical feature of Behçet’s disease is recurrent, acute anterior uveitis 
associated with hypopyon. Other ocular manifestations seen in Behçet’s disease 
include necrotizing vascular lesions involving the retina and the optic nerve. These 
manifestations may be unnoticed because of severity of the anterior segment reac-
tion and commonly include macular oedema, retinal periphlebitis and periarteritis, 
thrombosis of the vessels and retinal or vitreous haemorrhages which are frequently 
observed in males with Behçet’s disease [51, 52].
5.2 Oral manifestations
Recurrent oral ulcers are one of the earliest manifestations of Behçet’s disease 
in around 47–86% of patients and are seen in almost all patients during their clini-
cal course [53]. Other symptoms may at times take years to appear after the onset 
of disease. Oral ulcerative lesions usually manifest as a round- or oval-shaped 
ulcer with discrete erythematous border with a greyish-white pseudomembrane 
or a central yellowish fibrinous floor and grow rapidly from a flat ulcer to a deep 
sore [9]. They may occur as single ulcers or as numerous [9, 53]. Oral ulcers most 
commonly affect the gingival and buccal mucosa, tongue and lips yet may also 
appear in the soft and hard palates, pharynx and tonsils [9]. Minor ulcers which 
are less than 1 cm in diameter heal without scarring over a period of 1 to 2 weeks, 
whereas major ulcers which are more than 1 cm in diameter are more painful and 
heal within 2–6 weeks. Herpetiform ulcers occurring in recurrent crops of small 
ulcers that are 0.2–0.3 cm in diameter are painful and may coalesce to form large 
ulcers. Treatment is usually symptomatic, and prognosis of oral ulcerations is 
favourable [18, 53].
5.3 Cutaneous manifestations
The most commonly seen cutaneous manifestations are erythema nodosum and 
pseudofolliculitis, in which erythema nodosum is manifested as painful multiple 
subcutaneous nodules that vary in size and colour, whereas pseudofolliculitis (pus-
tulosis) appears as a dome-shaped sterile pustule on a round reddish edematous 
base that looks like acne vulgaris [54]. Although these are commonly seen on the 
lower extremities, it can be seen throughout the body [55]. The pathergy reaction 
is included in the criteria for the diagnosis of Behçet’s disease. Although more than 
50% of patients from Turkey and Japan had a positive pathergy test, it is rarely 
observed in patients from Northern Europe, the USA and Australia [56, 57]. It used 
to be an important diagnostic criterion for Behçet’s disease; however, the frequency 
of the pathergy phenomenon was reported to decrease during the recent years 
[58]. Subcutaneous thrombophlebitis is often confused with lesions of erythema 
nodosum; the former is manifested as tender erythematous nodules with a linear 
arrangement in most case. The lesions may relocate depending on the vascular 
segment involved [59].
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5.4 Cardiac manifestations
Cardiac involvement is a rare finding in patients with Behçet’s disease. Behçet’s 
disease affects arteries, veins as well as the heart. Cardiovascular features have 
been reported to affect 7–49% of patients, more frequently in males. They occur 
3–16 years after the onset of Behçet’s disease. Cardiac involvement in Behçet’s 
disease patients was first described by Mirone et al. in 1958 as a case of paroxysmal 
fibrillation and heart block. In 1963, Oshima et al. described a case of myocardial 
infarction complicated by incomplete right bundle-branch block [60]. Since then 
different types of cardiovascular lesions, including pericarditis, atrial thrombus, 
complex ventricular arrhythmia, myocardial infarction, heart block and sudden 
death, have been reported in association with Behçet’s disease [61]. Dong Soo et al. 
in 1998 reported a case of superior vena cava syndrome caused by Behçet’s disease 
in a 40-year-old man with recurrent oral aphthous ulcers and skin rashes on the 
anterior chest wall [62].
5.5 Neurological manifestations
Neurological involvement in Behçet’s disease, the neuro-Behçet’s disease, occurs 
very rarely and only in 5–10% of patients. It is frequently seen in males [63]. It 
usually occurs around 5 years after the onset of the disease and is associated with 
long-term morbidity and mortality [9]. Neuro-Behçet’s disease can be parenchymal, 
nonparenchymal or mixed brain disease, in which the parenchymal brain disease 
affects the brainstem and/or basal ganglia and is correlated with a poor prognosis, 
whereas nonparenchymal also known as vasculo-Behçet’s disease or angio-Behçet’s 
disease is characterised by subsets of cerebral venous thromboses, dural venous 
sinus thrombosis, arterial vasculitis and aseptic meningitis and comprises the most 
devastating symptom category of Behçet’s disease with high mortality [63, 64]. 
A mixed parenchymal and nonparenchymal disease has also been reported but is 
very rare. Infrequent clinical manifestations like epilepsy, stroke, brain tumour-like 
neuro-Behçet’s disease, acute meningeal syndrome, movement disorders, optic 
neuropathy, spinal cord involvement and asymptomatic and subclinical neurologi-
cal involvement have also been reported [65, 66]. Meningitis, neurological deficits 
including motor disturbances and brainstem symptoms and psychiatric symptoms 
including personality changes develop in patients with neuro-Behçet’s disease are 
considered as a classic finding [18, 63]. These symptoms are associated with disease 
exacerbations and gradually cause disability and unfortunately are irreversible 
[18]. At late stages, dementia develops in approximately one-third of patients with 
neuro-Behçet’s disease.
5.6 Gastrointestinal manifestations
Gastrointestinal involvement was observed in 3–26% of patients and varies 
among different populations [38, 39]. It is much more frequent in Japan than in the 
Middle East and the Mediterranean region [1–3]. Mucosal inflammation and ulcer-
ation can occur anywhere in the gastrointestinal tract but typically in the ileocecal 
region. Other rarely involved sites include the oesophagus, ascending colon and 
transverse colon [18, 19, 67]. Clinical symptoms include anorexia, vomiting, dys-
pepsia, diarrhoea, melena, abdominal pain and, less frequently, perforation requir-
ing surgical intervention [68]. Due to the similarity in intestinal and extraintestinal 
symptoms, it is tough to differentiate Behçet’s disease from inflammatory bowel 
disease; however, the presence of granulomata can be used to confirm inflamma-
tory bowel disease [66].
Different Aspects of Behçet’s Disease
10
5.7 Articular manifestations
Joint involvement is common in patients with Behçet’s disease seen in almost half 
of patients. It presents as an initial manifestation seen long before the commence-
ment of other features of BD [55]. Erosive, non-deforming oligoarthritis typically 
involving the knees, ankles and wrists is seen in most of the Behçet’s disease 
patients. Rarely, it can present as sacroiliitis or erosive arthritis. Myopathy has also 
been reported by Arkin in 1980 [69–72].
5.8 Vascular manifestations
Vasculitis is one of the classic signs in Behçet’s disease, and the typical finding 
is deep vein thrombosis. Thrombophlebitis occurs generally in the first year after 
onset of Behçet’s disease, and relapses are frequent. Vasculitis can affect both the 
veins and arteries and capillaries although venous involvement is more common 
[55]. Venous thrombosis may occur at any site and can even involve large vessels 
like the inferior vena cava, the superior vena cava and the pulmonary artery. [55]. 
Arterial involvement is seen in 3–5% of cases [73]. Aneurysm formation is found to 
be the foremost manifestation, and the affected patients can be asymptomatic [74]. 
Vascular surgery is mandatory, but relapse is a frequent concern [55].
5.9 Pulmonary manifestations
Pulmonary manifestations are rare in patients with Behçet’s disease. Haemoptysis 
is the only reported manifestation, but it can be massive and fatal [74].
6. Diagnostic criterion and activation markers in Behçet’s disease
The diagnosis of Behçet’s disease relies purely on its clinical manifestation since 
it lacks specific biological test, so diagnosis with clinical symptoms is challenging, 
especially due to non-concomitant symptoms. Hence different diagnostic criteria have 
been developed for the determination of Behçet’s disease. In 1990, an ISG for Behçet’s 
disease was formed by a group of researchers [21]. The International Study Group 
developed a set of classification criteria which is designed for research studies, which 
in many instances is used for diagnosing. The features were defined as the presence 
of specific symptoms as seen in Table 3. Oral ulceration along with any other two 
symptoms is said to be diagnostic [75]. The capability of the ISG criteria as a diagnostic 
tool has been questioned [56]. An international team which includes 27 countries was 
formed to evaluate and reassess the ISG criteria, and a new ICBD was developed that 
include the major criteria consisting of oral aphthosis, genital aphthosis and ocular 
lesions which were each given 2 points, whereas 1 point was assigned to the skin lesion, 
neurological manifestation, vascular manifestation and positive pathergy test (which 
is optional and not included in the primary criteria due to geographic variation and its 
declining sensitivity and increased specificity) [58, 75]. Higher sensitivity of the ICBD 
was reported as it aided in earlier diagnosis and hence earlier treatment and thereby 
better prognosis [75]. However, the delay between the onsets of major manifestations 
may be decades needs to be considered [76]. Inflammatory markers such erythrocyte 
sedimentation rate (ESR) and C-reactive protein have no longer been recognised as 
accurate or specific for the disease activity (Table 4).
Investigations for Behçet’s disease include routine total blood count; renal, liver and 
bone profile; inflammatory markers, including C-reactive protein and erythrocyte sedi-
mentation rate; urine analysis; chest X-ray; coeliac screen; stool sample; autoimmune 
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screen; coagulation profile and antiphospholipid antibodies; mouth and genital ulcer 
swab and culture; and occasionally eye swab. Other investigations that may be required 
include oral biopsy and direct immunofluorescence to exclude orofacial granulomatosis 
and bullous dermatosis. Vulval biopsy is indicated to exclude lichen sclerosis).
Doppler studies, CT or MRI brain and spinal cord, magnetic resonance venog-
raphy, computerised tomographic venography, magnetic resonance angiography, 
computerised tomography angiography to evaluate neurologic and vascular disease; 
CSF studies, electro encephalogram, electromyography, nerve conduction study, 
18 F fluoro2-deoxyglucose positron emission tomography, with CT/MRI localisation 
(for early inflammation in large vessel vasculitis). Musculoskeletal BD—syno-
vial fluid analysis, X-ray, ultrasound or MRI to evaluate joints. Skin biopsy and 
immunofluorescence for cutaneous involvement. Cardiac BD—electrocardiogram, 
echocardiogram in case of cardio vascular involvement chest CT to assess mediasti-
nal diseases, fibrosing mediastinitis, aneurysms, pleural effusions, complications of 
venous thrombosis and collaterals. Stool sample for faecal calprotectin, endoscopy 
and biopsy if there is Gastrointestinal involvement. Ocular BD—optical coher-
ence tomography, visual evoked potentials, fluorescein angiogram, Schirmer’s 
test, intraocular fluid culture to exclude infections in Behçets patients with ocular 
involvement. Cystoscopy and kidney, urinary bladder CT for urological disease [7].
7. Management
The multisystem involvement in Behçet’s systems alarms the requirement of a 
teamwork from different medical specialties such as oral medicine, ophthalmology, 
Recurrent oral 
ulcerations
Minor aphthous, major aphthous or herpetiform ulceration observed by physician 
or patient, which recurred at least three times in one 12-month period
Plus any two of the following
Recurrent genital 
ulceration
Aphthous ulceration or scarring observed by physician or patient
Eye lesion Anterior uveitis, posterior uveitis or cells in vitreous on slit lamp examination or 
retinal vasculitis observed by ophthalmologist
Skin lesions Erythema nodosum observed by physician or patient, pseudofolliculitis or 
papulopustular lesions or acneiform nodules observed by physician in post 
adolescent patients not on corticosteroid treatment
Positive pathergy test Read by a physician at 24–48 hours
Table 3. 
The international study group criteria for Behçet’s disease [21].
Symptoms Points
Oral aphthosis 2
Genital aphthosis 2
Ocular lesion 2
Skin lesion 1
Neurological manifestation 1
Vascular manifestation 1
Positive pathergy test 1b
Table 4. 
International criteria for Behçet’s disease [75].
Different Aspects of Behçet’s Disease
12
Manifestations Treatments
Mild mucocutaneous lesions Topical steroids
Moderate to severe 
mucocutaneous lesions
Initial: systemic steroid, colchicine
Refractory case: azathioprine, interferon𝛼
Ocular lesions Initial: systemic steroid + azathioprine
Refractory case: first cyclosporine A + steroid + azathioprine
Second interferon 𝛼+/− systemic steroid
Arthritis (First) colchicine nonsteroidal anti-inflammatory drug, (second) 
azathioprine, interferon 𝛼
Vascular: deep venous 
thrombosis
Azathioprine, cyclosporine A, cyclophosphamide (larger vessels)
Vascular: arterial aneurysm Cyclophosphamide + systemic steroid
Neurological Cyclophosphamide (drug of choice)
Gastrointestinal Systemic steroid, sulfasalazine, azathioprine
Table 5. 
Suggested management options of Behçet’s disease [78, 79].
Disease-modifying drugs (DMDs) Dosage
Oral DMDs
Azathioprine 2–3 mg/kg/day
Mycophenolate mofetil 2–3 g/day
Methotrexate 20–25 mg/week
Tacrolimus 4–8 mg/day
Ciclosporin 2–5 mg/kg/day
Sulfasalazine 2–3 g/day
Dapsone 2–3 mg/kg/day
Thalidomide (exceptional use) 50–300 mg/day
Colchicine 0.5–2 mg/day
Prednisolone Variable dose (depending on indication and stage of 
treatment)
Parenteral DMDs
Cyclophosphamide 15 mg/kg (vasculitis regimens)
Anti-TNF α inhibitors
Infliximab 5 mg/kg at 0, 2 and 6 weeks then once every 8 weeks
Adalimumab 40 mg every 2 weeks
Etanercept 50 mg/week
Certolizumab 400 mg at 0, 2 and 4 weeks then once every 4 week
Rituximab 1 g at 0 and 2 weeks
Interferon α Various regimens for Roferon A and pegylated 
interferon α 2b
Alemtuzumab 3 mg (day 1), 10 mg (day 3), 30 mg (day 5), 30 mg (day 
8), 30 mg (day 10) and 30 mg (day 12)
Table 6. 
Disease-modifying drugs used in Behçet’s disease [7].
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dermatology, rheumatology, neurology, cardiology and gastroenterology for its 
management. The main objective of management of Behçet’s disease is to induce 
and maintain remission and improve the patient’s quality of life, preventing irre-
versible damage and exacerbation of mucocutaneous and articular disease [77, 78]. 
Since Behçet’s disease has plethoric expressions, treatment plan may vary depend-
ing on severity, organ affected, age of disease onset, disease duration and frequency 
of recurrences [59].
The European League Against Rheumatism (EULAR) formed a committee in 
2008 to develop an evidence-based recommendation for the treatment modalities 
of Behçet’s disease [78]. Suggestions regarding ocular and mucocutaneous diseases 
and arthritis are primarily evidence-based, but recommendations on neurological, 
vascular and gastrointestinal involvement relied on observational studies, retro-
spective analyses and expert opinion [78].
Treatment of Behçet’s disease is mainly based on the suppression of the inflam-
matory attack using immunomodulatory agents such as corticosteroids, azathio-
prine or interferon 𝛼 [78]. The primary line of management of mucocutaneous 
lesions in Behçet’s disease is colchicine (1 mg/day). NSAID is usually sufficient 
for joint manifestations [54]. Clinicians should keep in mind the neurotoxicity of 
cyclosporine A while prescribing it to any patient with neurologic problems for 
treating vascular involvement and refractory eye disease [54]. Biologic agents are 
the only option if the disease seems to be resistant to treatments [78]. Suggested 
management options are summarised in Tables 5 and 6.
8. Conclusion
Behçet’s disease is a chronic, relapsing vasculitis with multisystem involvement 
with considerable morbidity and mortality. There exists a delay in the diagnosis of 
Behçet’s disease since it lacks a specific diagnostic test and biomarkers. Another area 
to be focussed on is to develop a more effective disease activity score. Researches 
are on the go to explore more about the disease’s pathophysiology which may aid in 
early diagnosing and effective treatment planning.
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